# MEDICATION GUIDE SPEVIGO<sup>®</sup> (spea VEE go) (spesolimab-sbzo)

#### injection, for subcutaneous or intravenous use

#### What is the most important information I should know about SPEVIGO?

# SPEVIGO may cause serious side effects, including:

- Infections. SPEVIGO may lower the ability of your or your child's immune system to fight infections and may
  increase your or your child's risk of infections. Your healthcare provider should check you or your child for
  infections and tuberculosis (TB) before starting treatment with SPEVIGO and may treat you or your child for TB
  before you begin treatment with SPEVIGO if you have a history of TB or have active TB. Your healthcare provider
  should watch you or your child closely for signs and symptoms of TB during or after treatment with SPEVIGO. Tell
  your healthcare provider right away if you or your child have an infection or have symptoms of an infection during or
  after treatment with SPEVIGO, including:
  - o fevers, chills, or sweats

- o blood in your phlegm (mucus)
- burning when you urinate

o cough

0

urinating more often than normal

o shortness of breath

muscle aches

 Allergic reactions and infusion-related reactions. Serious allergic reactions may happen during or after your or your child's SPEVIGO injection. If you or your child have a serious allergic reaction, your healthcare provider will stop treatment with SPEVIGO. If you or your child are given SPEVIGO in a vein (intravenously) and have an infusion-related reaction, your healthcare provider will stop your or your child's SPEVIGO infusion and treat your or your child's symptoms and may restart SPEVIGO at a slower infusion rate.

Tell your healthcare provider or get emergency medical help right away if you or your child get any of the following symptoms during or after your or your child's SPEVIGO injection:

0

- o feeling faint, dizzy, or lightheaded
- o chest tightness
- swelling of your face, eyelids, lips, mouth, tongue, or throat
- from generalized pustular psoriasis (GPP) o itching

hives or skin rash that is different than the rash

- o trouble breathing or throat tightness
- o swollen lymph nodes

fevermouth sores

### See "What are the possible side effects of SPEVIGO?" for more information about side effects.

### What is SPEVIGO?

SPEVIGO is a prescription medicine used to treat generalized pustular psoriasis (GPP) in adults and children 12 years of age and older who weigh at least 88 pounds (40 kg).

It is not known if SPEVIGO is safe and effective in children under 12 years of age or who weigh less than 88 pounds (40 kg).

**Do not receive SPEVIGO if you or your child** have had a severe or life-threatening allergic reaction to spesolimabsbzo or any of the ingredients in SPEVIGO. See the end of this Medication Guide for a complete list of ingredients in SPEVIGO.

# Before you or your child receive SPEVIGO, tell your healthcare provider about all of your medical conditions, including if you or your child:

- have an infection that does not go away or that keeps coming back. See "What is the most important information I should know about SPEVIGO?"
- have TB or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). You or your child should not receive live vaccines during and for at least 16 weeks after treatment with SPEVIGO. You or your child should be brought up to date with all vaccines before starting SPEVIGO.
- are pregnant or plan to become pregnant. It is not known if SPEVIGO can harm your or your child's unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if SPEVIGO passes into your breast milk. Talk to your healthcare provider about the best way to feed your or your child's baby during treatment with SPEVIGO.

Tell your healthcare provider about all the medicines you or your child take, including prescription and over-thecounter medicines, vitamins, and herbal supplements.

# How will I receive SPEVIGO?

When given under the skin (subcutaneously) for treatment of GPP when not experiencing a flare:

- Read the detailed "Instructions for Use" that comes with SPEVIGO for information on how to prepare and inject a dose of SPEVIGO and how to properly throw away (dispose of) used SPEVIGO prefilled syringes.
- Your healthcare provider will tell you how much SPEVIGO to inject and when to inject it. Use SPEVIGO exactly as your healthcare provider tells you to use it.
- If your healthcare provider decides that you or a caregiver can give your or your child's injections of SPEVIGO at home, you should receive training on the right way to prepare and inject SPEVIGO. Do not try to inject SPEVIGO until you have been shown the right way by your healthcare provider. In children 12 to 17 years of age, SPEVIGO should be given under supervision of an adult.
- If you miss a dose of SPEVIGO, inject your or your child's dose as soon as possible. Then, inject your or your child's next dose at the regular scheduled time. In case you are not sure when to inject SPEVIGO, call your healthcare provider.

# When given in a vein (intravenously) for GPP flare treatment:

- Your healthcare provider will give you or your child SPEVIGO through a needle placed in your vein (intravenous infusion) over 90 minutes.
- SPEVIGO is usually given one time. If GPP flare symptoms continue, your healthcare provider will decide if you should receive an additional treatment with SPEVIGO after 1 week.

### What are the possible side effects of SPEVIGO?

SPEVIGO may cause serious side effects. See "What is the most important information I should know about SPEVIGO?"

# The most common side effects of SPEVIGO for GPP flare treatment include:

- feeling tired or weak
- nausea and vomiting

 a collection of blood under the skin at the infusion site or bruising

• headache

urinary tract infection

itching or itchy bumps

### The most common side effects of SPEVIGO for treatment of GPP when not experiencing a flare include: • redness pain swelling hardening hives • urinary tract infection

- redness, pain, swelling, hardening, hives, or warmth at the injection site
- urinary tract infectionitching

• joint pain

These are not all of the possible side effects of SPEVIGO.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

# How should I store SPEVIGO?

- Store SPEVIGO prefilled syringes in the refrigerator between 36°F to 46°F (2°C to 8°C).
- **Do not** freeze SPEVIGO. Do not use SPEVIGO if frozen, even if it has been thawed.
- Store SPEVIGO in the original carton until use to protect from light.

# Keep SPEVIGO and all medicines out of the reach of children.

### General information about the safe and effective use of SPEVIGO.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use SPEVIGO for a condition for which it was not prescribed. Do not give SPEVIGO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about SPEVIGO that is written for health professionals.

### What are the ingredients in SPEVIGO?

Active ingredient: spesolimab-sbzo

**Inactive ingredients:** arginine hydrochloride, glacial acetic acid, polysorbate 20, sodium acetate, sucrose, and Water for Injection

Manufactured by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 USA

US License Number 2006

Licensed from: Boehringer Ingelheim International GmbH, Ingelheim, Germany

SPEVIGO is a registered trademark of and used under license from Boehringer Ingelheim International GmbH. Copyright © 2024 Boehringer Ingelheim International GmbH ALL RIGHTS RESERVED COL9614BC152024 For more information about SPEVIGO, including current prescribing information and Medication Guide, go to **www.SPEVIGO.com**, so

For more information about SPEVIGO, including current prescribing information and Medication Guide, go to **www.SPEVIGO.com**, scan the code below, or call Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257.



This Medication Guide has been approved by the U.S. Food and Drug Administration.

Revised: 03/2024